Form 13-F position report

HAEMONETICS CORP MASS

Reported by BEACON INVESTMENT ADVISORS LLC

HAE 0 03/01/26 CUSIP 405024AB6 Manager CIK 0001961635

Reported 64,000 shares, unchanged from the prior quarter.

Reported value 0.3%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.04% This manager · Q2 2023
Shares 64,000 Quarter-end amount reported
Reported value $54,458 Fair value at quarter end
Consecutive quarters held 3 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-12-31 37184
2023-03-31 54303
2023-06-30 54458
2023-09-30 55520
2023-12-31 56960
2024-03-31 58758
2024-06-30 57376
2024-09-30 58880
2024-12-31 60243
2025-03-31 61082
2025-06-30 61670
2025-09-30 76245
2025-12-31 77025
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for HAEMONETICS CORP MASS held by BEACON INVESTMENT ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -78,000 (-100.0%) 0 $0 2026-05-14
Q4 2025 Unchanged 78,000 0 (0.0%) 0.03% $77,025 2026-02-17
Q3 2025 Added 78,000 +14,000 (21.9%) 0.03% $76,245 2025-11-14
Q2 2025 Unchanged 64,000 0 (0.0%) 0.03% $61,670 2025-08-14
Q1 2025 Unchanged 64,000 0 (0.0%) 0.03% $61,082 2025-05-15
Q4 2024 Unchanged 64,000 0 (0.0%) 0.03% $60,243 2025-02-14
Q3 2024 Unchanged 64,000 0 (0.0%) 0.03% $58,880 2024-11-14
Q2 2024 Unchanged 64,000 0 (0.0%) 0.03% $57,376 2024-08-14
Q1 2024 Unchanged 64,000 0 (0.0%) 0.03% $58,758 2024-05-13
Q4 2023 Unchanged 64,000 0 (0.0%) 0.04% $56,960 2024-02-13
Q3 2023 Unchanged 64,000 0 (0.0%) 0.04% $55,520 2023-11-07
Q2 2023 Unchanged 64,000 0 (0.0%) 0.04% $54,458 2023-08-03
Q1 2023 Added 64,000 +19,000 (42.2%) 0.04% $54,303 2023-05-12
Q4 2022 New 45,000 +45,000 (0.0%) 0.03% $37,184 2023-02-09

Who else reported the position

57 managers reported HAEMONETICS CORP MASS for Q2 2023.

Managers reporting HAEMONETICS CORP MASS in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ADVENT CAPITAL MANAGEMENT DE Reduced 53,348,000 -6,705,000 0.88% $45,660,417 6 qtrs
FRANKLIN RESOURCES INC Unchanged 50,000,000 0 0.02% $42,794,875 6 qtrs
Linden Advisors LP Added 40,483,000 +18,156,000 0.36% $34,631,670 4 qtrs
WOLVERINE ASSET MANAGEMENT LLC Unchanged 0 0 0.4% $33,498,151 4 qtrs
AVIVA PLC Unchanged 30,000,000 0 0.1% $25,588,230 6 qtrs
MACKAY SHIELDS LLC Added 29,499,000 +9,708,000 0.7% $25,204,736 6 qtrs
OAKTREE CAPITAL MANAGEMENT LP Added 26,145,000 +1,025,000 0.29% $22,377,439 6 qtrs
DeepCurrents Investment Group LLC Added 24,371,000 +3,621,000 0.82% $20,841,796 4 qtrs
Aequim Alternative Investments LP Unchanged 20,500,000 0 0.66% $17,545,898 6 qtrs
OSTERWEIS CAPITAL MANAGEMENT INC Unchanged 18,000,000 0 1.02% $15,406,154 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 03, 2023
Filing type
13F-HR
Position type
NOTE 3/0

Voting authority reported

Sole
0
Shared
0
None
64,000

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.